HIGHLIGHTS
- who: October et al. from the Amity University, India have published the article: A perspective on oligonucleotide therapy: Approaches to patient customization, in the Journal: (JOURNAL) of 23/09/2022
- what: The success stories of Fomivirsen, pegaptanib, and patisiran give hope for developing many more ON therapeutics.
- how: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- future: Both RNAi therapeutics-siRNA and miRNA-hold a great place as a new therapeutic class . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.